Flowvium

公司比较

并排比较供应链位置、机构信号和新闻间隙评分。

VS

市值区间

超大型vs巨型

链条角色

leadervsleader

间隙评分

N/AvsN/A

IB活动

N/AvsN/A

营收结构比较

NVO
NVDA
NVO

Novo Nordisk

NVO · pharma-biotech

leader超大型 ($100B+)
完整资料

简介

Novo Nordisk is the global leader in diabetes care and has become a GLP-1 giant with Ozempic and Wegovy. The obesity-drug revolution has made it Europe's most valuable company. Its near-monopoly on injectable semaglutide positions it at the center of the $100B+ weight-loss drug market.

成立时间

1923

员工人数

64,000+

总部

Bagsvaerd, Denmark

营收

$42.6B

GLP-1 Diabetes (Ozempic, Rybelsus)42%
Obesity (Wegovy)25%
Insulin20%
Rare Disease & Other13%

新闻缺口信号

此股票代码没有新闻缺口数据。

机构信号

此代码没有13F信号记录。

关键关系

LLY· Eli Lilly and Company
competitor
PFE· Pfizer Inc.
competitor
NVD

NVIDIA Corporation

NVDA · semiconductors

leader巨型 ($1T+)
完整资料

简介

NVIDIA is the dominant designer of graphics processing units and AI accelerator chips. Its data-center GPU monopoly powers the generative-AI revolution, with the H100 and successor Blackwell GPUs serving as the de-facto standard for training and running large language models.

成立时间

1993

员工人数

32,000+

总部

Santa Clara, California, USA

营收

$130.5B

Data Center78%
Gaming12%
Professional Visualization4%
Automotive & Robotics4%
OEM & Other2%

新闻缺口信号

此股票代码没有新闻缺口数据。

机构信号

此代码没有13F信号记录。

关键关系

TSM· Taiwan Semiconductor Manufacturing Company
supplier
005930.KS· Samsung Electronics
supplier
000660.KS· SK Hynix
supplier
MU· Micron Technology
supplier
MSFT· Microsoft Corporation
customer